First, the in vitro studies of primary CML cells in response to the catalytic mTOR inhibitor(s) presented here were confined to a relatively small number of TKI-resistant CML patients’ samples. This evidence concerns the gene MTOR and chronic myelogenous leukemia, BCR-ABL1 positive.